Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 77Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 1863Lung Neoplasms 1292Small Cell Lung Carcinoma 324Colorectal Neoplasms 273Breast Neoplasms 242Melanoma 221Neoplasms 215Ovarian Neoplasms 192Neoplasm Metastasis 182Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 150Stomach Neoplasms 141Head and Neck Neoplasms 121Carcinoma, Renal Cell 119Triple Negative Breast Neoplasms 109Esophageal Neoplasms 108Prostatic Neoplasms 106Endometrial Neoplasms 98Uterine Cervical Neoplasms 96Urinary Bladder Neoplasms 87Colonic Neoplasms 87Mesothelioma 86Mesothelioma, Malignant 80Carcinoma, Hepatocellular 74Brain Neoplasms 70Sarcoma 63Disease 62Adenocarcinoma of Lung 59Carcinoma, Transitional Cell 54Gastrointestinal Neoplasms 50

Interventions

amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Thoracic × 1 year × Clear all
NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

ORIC Pharmaceuticals

Phase 1 Recruiting
76 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡